Literature DB >> 24760540

Association of HDL-C and apolipoprotein A-I with the risk of type 2 diabetes in subjects with impaired fasting glucose.

You-Cheol Hwang1, Hong-Yup Ahn1, Sung-Woo Park1, Cheol-Young Park2.   

Abstract

OBJECTIVES: HDLs have many diverse functions. The goal of this study was to determine the association of HDL cholesterol (HDL-C) and apolipoprotein A-I (apoA-I) with the development of type 2 diabetes (T2D). In particular, this study determined the association between the ratio of HDL-C to apoA-I (HA) and incident T2D. DESIGN AND METHODS: A total of 27 988 subjects with impaired fasting glucose (IFG) (18 266 men and 9722 women) aged 21-91 years (mean age 40.7 years) were followed for a mean duration of 2.81 years.
RESULTS: Study subjects were divided into quartiles according to the baseline HA ratio. Age, male sex, current smoking, BMI, waist circumference, and high-sensitivity C-reactive protein decreased across the quartiles, and all metabolic profiles, including blood pressure, fasting glucose, insulin resistance as determined by homeostasis model assessment of insulin resistance, and lipid measurements such as total cholesterol, LDL cholesterol, non-HDL-C, and apoB, improved as the HA ratio increased. In addition, incident cases of T2D decreased as the HA ratio increased, independent of age, sex, BMI, current smoking, systolic blood pressure, HbA1c, fasting serum insulin, family history of diabetes, and serum triglyceride concentrations (HR (95% CI) of fourth quartile vs first quartile; 0.76 (0.67-0.86), P<0.0001).
CONCLUSIONS: A higher HA ratio was associated with favorable metabolic profiles and a lower risk of T2D development in subjects with IFG.
© 2014 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24760540     DOI: 10.1530/EJE-14-0195

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

Review 1.  HDL and Reverse Cholesterol Transport.

Authors:  Mireille Ouimet; Tessa J Barrett; Edward A Fisher
Journal:  Circ Res       Date:  2019-05-10       Impact factor: 17.367

Review 2.  The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.

Authors:  Marek Femlak; Anna Gluba-Brzózka; Aleksandra Ciałkowska-Rysz; Jacek Rysz
Journal:  Lipids Health Dis       Date:  2017-10-30       Impact factor: 3.876

3.  Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.

Authors:  Liliana Fonseca; Sílvia Paredes; Helena Ramos; José Carlos Oliveira; Isabel Palma
Journal:  Lipids Health Dis       Date:  2020-06-06       Impact factor: 3.876

4.  Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study.

Authors:  Liang Gao; Yaju Zhang; Xingmin Wang; Hongli Dong
Journal:  BMC Endocr Disord       Date:  2021-04-01       Impact factor: 2.763

Review 5.  High Density Lipoproteins and Diabetes.

Authors:  Blake J Cochran; Kwok-Leung Ong; Bikash Manandhar; Kerry-Anne Rye
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

6.  High-density lipoprotein-cholesterol and incident type 2 diabetes mellitus among African Americans: The Jackson Heart Study.

Authors:  Dayawa D Agoons; Solomon K Musani; Adolfo Correa; Sherita H Golden; Alain G Bertoni; Justin B Echouffo-Tcheugui
Journal:  Diabet Med       Date:  2022-06-16       Impact factor: 4.213

7.  Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans.

Authors:  You-Cheol Hwang; Tomoshige Hayashi; Wilfred Y Fujimoto; Steven E Kahn; Donna L Leonetti; Marguerite J McNeely; Edward J Boyko
Journal:  Diabetes Care       Date:  2015-09-17       Impact factor: 19.112

8.  Role of High-Density Lipoproteins in Cholesterol Homeostasis and Glycemic Control.

Authors:  Bikash Manandhar; Blake J Cochran; Kerry-Anne Rye
Journal:  J Am Heart Assoc       Date:  2019-12-31       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.